Erlotinib
- Generic Name
- Erlotinib
- Brand Names
- Tarceva
- Drug Type
- Small Molecule
- Chemical Formula
- C22H23N3O4
- CAS Number
- 183321-74-6
- Unique Ingredient Identifier
- J4T82NDH7E
- Background
Erlotinib is an inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that is used in the treatment of non-small cell lung cancer, pancreatic cancer and several other types of cancer. It is typically marketed under the trade name Tarceva. Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. Recent studies demonstrate that erlotinib is also a potent inhibitor of JAK2V617F, which is a mutant form of tyrosine kinase JAK2 found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. This finding introduces the potential use of erlotinib in the treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
- Indication
Erlotinib is indicated for:
The safety and efficacy of erlotinib have not been established for patients with NSCLC whose tumors show other EGFR mutations. Additionally it is not recommended for use in combination with platinum-based chemotherapy.
- Associated Conditions
- Locally Advanced Pancreatic Cancer (LAPC), Metastatic Non-Small Cell Lung Cancer, Pancreatic Metastatic Cancer, Unresectable Pancreatic Cancer
- Associated Therapies
- -
A Phase 1 Dose-escalation Study of OSI-906 and Erlotinib (Tarceva®)
- First Posted Date
- 2008-08-21
- Last Posted Date
- 2024-11-20
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 95
- Registration Number
- NCT00739453
- Locations
- 🇺🇸
University of Colorado Health Science Center, Aurora, Colorado, United States
🇺🇸Hudson-Webber Cancer Research Center, Karmanos Cancer Institute, Detroit, Michigan, United States
🇬🇧University of Oxford Department of Medical Oncology, Oxford, United Kingdom
Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers
- Conditions
- Interventions
- First Posted Date
- 2008-08-20
- Last Posted Date
- 2015-02-04
- Target Recruit Count
- 44
- Registration Number
- NCT00738751
- Locations
- 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site
- Conditions
- Interventions
- First Posted Date
- 2008-08-18
- Last Posted Date
- 2016-08-17
- Lead Sponsor
- SCRI Development Innovations, LLC
- Target Recruit Count
- 289
- Registration Number
- NCT00737243
- Locations
- 🇺🇸
Oncology Hematology Associates of SW Indiana, Evansville, Indiana, United States
🇺🇸Wellstar Cancer Research, Marietta, Georgia, United States
🇺🇸Integrated Community Oncology Network, Jacksonville, Florida, United States
SCH 727965 in Patients With Advanced Breast and Lung Cancers (Study P04716)
- Conditions
- Interventions
- First Posted Date
- 2008-08-12
- Last Posted Date
- 2015-08-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 97
- Registration Number
- NCT00732810
Phase II Study Of Neoadjuvant Chemotherapy In Borderline Resectable Pancreatic Adenocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2008-08-05
- Last Posted Date
- 2019-11-25
- Lead Sponsor
- University of Cincinnati
- Registration Number
- NCT00728000
- Locations
- 🇺🇸
University of Cincinnati, Cincinnati, Ohio, United States
APRiCOT-P: Study of Apricoxib With Gemcitabine and Erlotinib to Treat Advanced Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2012-11-07
- Lead Sponsor
- Tragara Pharmaceuticals, Inc.
- Target Recruit Count
- 109
- Registration Number
- NCT00709826
- Locations
- 🇺🇸
The Queen's Medical Center Cancer Center, Honolulu, Hawaii, United States
🇺🇸Front Range Cancer Specialists, Ft. Collins, Colorado, United States
🇺🇸Bronx River Medical Associates, P.C., Bronx, New York, United States
Early Prediction of Therapeutic Response to Targeted Therapy in Stage IIIB/IV or Recurrent Lung Cancer Patients
- Conditions
- Interventions
- First Posted Date
- 2008-07-02
- Last Posted Date
- 2024-11-14
- Lead Sponsor
- University of Utah
- Target Recruit Count
- 26
- Registration Number
- NCT00708448
- Locations
- 🇺🇸
Huntsman Cancer Institute, Salt Lake City, Utah, United States
Study of Oral Vinorelbine and Erlotinib in Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2012-10-19
- Lead Sponsor
- National Cancer Centre, Singapore
- Target Recruit Count
- 30
- Registration Number
- NCT00702182
- Locations
- 🇸🇬
National Cancer Center Singapore, Singapore, Singapore
A Study of First Line Treatment With Tarceva (Erlotinib) in Combination With Gemcitabine in Patients With Unresectable Advanced and/or Metastatic Non-Small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-19
- Last Posted Date
- 2016-06-24
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 20
- Registration Number
- NCT00701558
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-06-30
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 45
- Registration Number
- NCT00696696
- Locations
- 🇺🇸
Desert Regional Medical Center, Palm Springs, California, United States
🇺🇸Bellevue Hospital, New York, New York, United States
🇺🇸New York University Cancer Center, New York, New York, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.